Transfusion Medicine Reviews
Volume 22, Issue 1 , Pages 1-34 , January 2008

Proceedings of a Consensus Conference: Pathogen Inactivation—Making Decisions About New Technologies

References 

  1. Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: making decisions about new technologies—Preliminary report of a consensus conference. Vox Sang. 2007;93:179–182
  2. Busch MP. Transfusion-transmitted viral infections: Building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis. Transfusion. 2006;46:1624–1640
  3. Murphy W. Managing threats rather than risks in blood transfusion: Robust design for a complex system. Transfusion. 2006;46:2011–2013
  4. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998;11:480–496
  5. Stramer SL, Fang CT, Foster GA, et al. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med. 2005;353:451–459
  6. Klein HG, Dodd RY, Dzik WH, et al. Current status of solvent/detergent-treated frozen plasma. Transfusion. 1998;38:102–107
  7. Bryant BJ, Klein HG. Pathogen inactivation: The definitive safeguard for the blood supply. Arch Pathol Lab Med. 2007;131:719–733
  8. Wagner SJ. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus Med Rev. 2002;16:61–66
  9. Hanson CV. Photochemical inactivation of viruses with psoralens: an overview. Blood Cells. 1992;18:7–25
  10. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood. 1998;91:2180–2188
  11. Ennever JF, Speck WT. Short communication. Photochemical reactions of riboflavin: Covalent binding to DNA and to poly (dA). poly (dT). Pediatr Res. 1983;17:234–236
  12. Ito K, Inoue S, Yamamoto K, et al. 8-Hydroxydeoxyguanosine formation at the 5′ site of 5′-GG-3′ sequences in double-stranded DNA by UV radiation with riboflavin. J Biol Chem. 1993;268:13221–13227
  13. Corash L. Helinx technology for inactivation of infectious pathogens and leukocytes in labile blood components: from theory to clinical application. Transfus Apheresis Sci. 2001;25:179–181
  14. Purmal A, Valeri CR, Dzik W, et al. Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: Preclinical studies. Transfusion. 2002;42:139–145
  15. McQueen CA, Devito M, Chapin R, et al. Definition of toxicology. Society of Toxicology web site. http://www.toxicology.org/ai/pub/si05/SI05_Define.asp[accessed August 27, 2007]
  16. Ciaravino V. Preclinical safety of a nucleic acid-targeted Helinx compound: A clinical perspective. Semin Hematol. 2001;38:12–19
  17. Ciaravino V, McCullough T, Cimino G. The role of toxicology assessment in transfusion medicine. Transfusion. 2003;43:1481–1492
  18. Chapman JR, Moore K, Butterworth BE. Pathogen inactivation of RBCs: PEN110 reproductive toxicology studies. Transfusion. 2003;43:1386–1393
  19. Ciaravino V, McCullough T, Cimino G, et al. Preclinical safety profile of plasma prepared using the INTERCEPT Blood System. Vox Sang. 2003;85:171–182
  20. Ciaravino V, McCullough T, Dayan AD. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol. 2001;20:533–550
  21. Butterworth BE, Chapman J. Exposure of hematopoietic stem cells to ethylene oxide during processing represents a potential carcinogenic risk for transplant recipients. Regul Toxicol Pharmacol. 2007;[E-publication 01 Aug 2007]
  22. Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma: A virus-inactivated substitute for fresh frozen plasma. Blood. 1992;79:826–831
  23. Biesert L, Suhartono H. Solvent/detergent treatment of human plasma—A very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Vox Sang. 1998;74:207–212[Suppl 1]
  24. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion. 1997;37:423–435
  25. Lambrecht B, Mohr H, Knuver-Hopf J, et al. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang. 1991;60:207–213
  26. Goodrich RP. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang. 2000;78:211–215[Suppl 2]
  27. Flamholz R, Jeon HR, Baron JM, et al. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: Is its decreased protein S activity clinically related to their development of deep venous thromboses?. J Clin Apheresis. 2000;15:169–172
  28. Coignard B, Nguyen GT, Tokars J, et al. A cluster of intra-operative deaths in a liver transplant center associated with the use of solvent/detergent plasma. [abstract] In: Proceedings of the 11th Annual Meetings of the Society for Healthcare Epidemiology of America. 2001;
  29. Yarranton H, Cohen H, Pavord SR, et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol. 2003;121:778–785
  30. Williamson LM, Llewelyn CA, Fisher NC, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion. 1999;39:1227–1234
  31. Williamson LM, Llewelyn CA. Efficacy of SD-treated plasma during liver transplantation (reply). [letter] Transfusion. 2000;40:887–888
  32. Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, et al. Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe?. Transfus Med. 2006;16:266–275
  33. Heger A, Romisch J, Svae TE. A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. Transfus Apheresis Sci. 2006;35:223–233
  34. Hellstern P. Solvent/detergent-treated plasma: Composition, efficacy, and safety. Curr Opin Hematol. 2004;11:346–350
  35. Stanworth SJ, Brunskill SJ, Hyde CJ, et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol. 2004;126:139–152
  36. Simonsen AC, Sorensen H. Clinical tolerance of methylene blue virus–inactivated plasma. A randomized crossover trial in 12 healthy human volunteers. Vox Sang. 1999;77:210–217
  37. Wieding JU, et al. Prospective randomized and controlled trial on solvent/detergent plasma versus methylene blue light inactivated plasma. [abstract] Transfusion. 2007;39:23S;[Suppl]
  38. Varez-Larran A, Del RJ, Ramirez C, et al. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang. 2004;86:246–251
  39. de la RJ, Arriaga F, Linares D, et al. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol. 2001;114:721–723
  40. del Rio-Garma J, Alvarex-Larran A, Martinez C, et al. Methylene blue photoinactivated plasma (MBPIP) vs fresh frozen plasma (FFP) in the treatment of idiopathic thrombotic thrombocytopenic purpura (TTP): a multicentre prospective-cohort study. [abstract] Vox Sang. 2007;93:41;[suppl 1]
  41. Atance R, Pereira A, Ramirez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion. 2001;41:1548–1552
  42. Osselaer JC, Debry C, Goffaux M, et al. Coagulation function in fresh frozen plasma prepared with two photochemical treatment methods. [abstract] Vox Sang. 2006;91:183;[Suppl 3]
  43. Politis C, Kavallierou L, Hantziara S, et al. Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience. Vox Sang. 2007;92:319–326
  44. Pehta JC. Clinical studies with solvent detergent–treated products. Transfus Med Rev. 1996;10:303–311
  45. Chekrizova V, Murphy WG. Solvent-detergent plasma: Use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies. Transfus Med. 2006;16:85–91
  46. Mintz PD, Bass NM, Petz LD, et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood. 2006;107:3753–3760
  47. Mintz PD, Neff A, MacKenzie M, et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion. 2006;46:1693–1704
  48. Jackson BR, AuBuchon JP, Birkmeyer JD. Update of cost-effectiveness analysis for solvent-detergent–treated plasma. [letter] JAMA. 1999;282:329
  49. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion. 1999;39:479–487
  50. Riedler GF, Haycox AR, Duggan AK, et al. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang. 2003;85:88–95
  51. Goodrich RP, Li J, Pieters H, et al. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang. 2006;90:279–285
  52. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion. 2005;45:1335–1341
  53. Snyder E, Raife T, Lin L, et al. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion. 2004;44:1732–1740
  54. Harker LA, Slichter SJ. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med. 1972;287:155–159
  55. Slichter SJ, Raife TJ, Davis K, et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion. 2006;46:731–740
  56. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial. Blood. 2004;104:1534–1541
  57. van Rhenen RD, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The euroSPRITE trial. Blood. 2003;101:2426–2433
  58. Janetzko K, Cazenave JP, Kluter H, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion. 2005;45:1443–1452
  59. Pickard C, AuBuchon JP, Tosteson ANA, et al. Influence of gender and collection order on radiolabeled red blood cell recovery. [abstract] Transfusion. 1995;35:6S;[Suppl]
  60. US Food and Drug Administration . Blood Products Advisory Committee transcript. Blood Products Advisory Committee. http://www.fda.gov/OHRMS/DOCKETS/ac/04/transcripts/2004-4057t1.htm2004;[accessed August 27, 2007]
  61. AuBuchon JP, Pickard CA, Herschel LH, et al. Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: A phase I clinical study. Transfusion. 2002;42:146–152
  62. Rios JA, Hambleton J, Viele M, et al. Viability of red cells prepared with S-303 pathogen inactivation treatment. Transfusion. 2006;46:1778–1786
  63. Benjamin RJ, McCullough J, Mintz PD, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: A phase III clinical trial in cardiac surgery patients. Transfusion. 2005;45:1739–1749
  64. Wagner SJ. Pathogen inactivation. In: Presented at AABB Annual Meeting, Seattle, WA. 2005;
  65. Lublin DM. Universal RBCs. Transfusion. 2000;40:1285–1289
  66. Garratty G. Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs. Transfus Med Rev. 2004;18:245–256
  67. Garratty G. In vitro reactions with red blood cells that are not due to blood group antibodies: A review. Immunohematol. 1998;14:1–11
  68. Conlan MG, Stassinopoulos A, Garratty G, et al. Antibody formation to S-303–treated RBCs in setting of chronic RBC transfusion. [abstract] Blood. 2004;104:112a;[Suppl]
  69. North A, Garratty G, Schott M, et al. A modified process for preparation of S-303 RBCs for pathogen inactivation substantially reduces potential for reactivity. [abstract] Transfusion. 2006;46:116A;[Suppl]
  70. Stassinopoulos A, Schott MA, Castro GM. Modification of the S-303 RBC pathogen inactivation process results in normal S-303 RBC viability in rabbits hyper-immunized to S-303 [abstract]. Vox Sang. 2005;89:138–139[Supp]
  71. Stainsby D, Jones H, Asher D, et al. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev. 2006;20:273–282
  72. Dzik WH, Murphy MF, Andreu G, et al. An international study of the performance of sample collection from patients. Vox Sang. 2003;85:40–47
  73. Murphy MF, Stearn BE, Dzik WH. Current performance of patient sample collection in the UK. Transfus Med. 2004;14:113–121
  74. Figueroa PI, Ziman A, Wheeler C, et al. Nearly two decades using the check-type to prevent ABO incompatible transfusions: One institution's experience. Am J Clin Pathol. 2006;126:422–426
  75. Cserti CM, Ward M, Uhl L. Impact of a policy to use only group O red cell transfusions for recipients with fewer-than-twice established ABO types: A feasible means to reduce potential ABO incompatible transfusion errors. [abstract] Blood. 2006;108:289a;[Suppl]
  76. Denomme GA, Van OM. High-throughput multiplex single-nucleotide polymorphism analysis for red cell and platelet antigen genotypes. Transfusion. 2005;45:660–666
  77. Vostal J. Update on bacterial contamination. In: Presentation at 2005 AABB Annual Meeting, slide 18. 2005;
  78. FDA Center for Drug Evaluation and Research Guidance documents. http://fda.gov/cder/guidance/index.htm#pharmacology/toxicology[Accessed August 27, 2007]
  79. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest. 2006;116:3211–3219
  80. Pitchford SC, Momi S, Giannini S, et al. Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood. 2005;105:2074–2081
  81. Kupatt C, Wichels R, Horstkotte J, et al. Molecular mechanisms of platelet-mediated leukocyte recruitment during myocardial reperfusion. J Leukoc Biol. 2002;72:455–461
  82. Benjamin RJ. In: Presentation at AABB Annual Meeting. 2006;
  83. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA. 1983;249:1743–1745
  84. Snyder E, McCullough J, Slichter SJ, et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: The SPRINT trial. Transfusion. 2005;45:1864–1875
  85. Offergeld R, Faensen D, Ritter S, et al. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: Risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill. 2005;10:8–11
  86. German haemovigilance, Paul-Ehrlich-Institute. 2007.
  87. Schrezenmeier H, Walther-Wenke G, Muller TH, et al. Bacterial contamination of platelet concentrates: Results of a prospective multicenter study comparing pooled whole blood–derived platelets and apheresis platelets. Transfusion. 2007;47:644–652
  88. Knutson F, Alfonso R, Dupuis K, et al. Photochemical inactivation of bacteria and HIV in buffy-coat–derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang. 2000;78:209–216
  89. Sachs UJ, Kauschat D, Bein G. White blood cell–reactive antibodies are undetectable in solvent/detergent plasma. Transfusion. 2005;45:1628–1631
  90. Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: An overview. Transfus Apheresis Sci. 2006;35:83–90
  91. Custer B. Economic analyses of blood safety and transfusion medicine interventions: A systematic review. Transfus Med Rev. 2004;18:127–143
  92. van Hulst M, De Wolf JT, Staginnus U, et al. Pharmaco-economics of blood transfusion safety: Review of the available evidence. Vox Sang. 2002;83:146–155
  93. AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of solvent-detergent–treated plasma. In search of a zero-risk blood supply. JAMA. 1994;272:1210–1214
  94. Riedler GF, Haycox AR, Duggan AK, et al. Solvent-detergent–treated plasma may be cost-effective. Vox Sang. 2003;84:334–335
  95. Bell CE, Botteman MF, Gao X, et al. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther. 2003;25:2464–2486
  96. Staginnus U, Corash L. Economics of pathogen inactivation technology for platelet concentrates in Japan. Int J Hematol. 2004;80:317–324
  97. Janssen MP, van der Poel CL, Buskens E, et al. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion. 2006;46:956–965
  98. Postma MJ, van Hulst M, De Wolf JT, et al. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med. 2005;15:379–387
  99. Moeremans K, Warie H, Annemans L. Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfus Med. 2006;16:17–30
  100. Trannoy LL, Lagerberg JW, Dubbelman TM, et al. Positively charged porphyrins: A new series of photosensitizers for sterilization of RBCs. Transfusion. 2004;44:1186–1196
  101. Trannoy LL, Terpstra FG, de KD, et al. Differential sensitivities of pathogens in red cell concentrates to Tri-P(4)–photoinactivation. Vox Sang. 2006;91:111–118
  102. Wagner SJ, Skripchenko A, Salata J, et al. Photoinactivation of Leishmania donovani infantum in red cell suspensions by a flexible thiopyrylium sensitizer. Vox Sang. 2006;91:178–180
  103. Skripchenko A, Balch A, Mackin A, et al. In vivo recovery and survival of red cells after photodynamic treatment with thiopyrylium and red light using a canine model. Vox Sang. 2007;92:157–159
  104. Skripchenko A, Wagner SJ, Thompson-Montgomery D, et al. Thiazole orange, a DNA-binding photosensitizer with flexible structure, can inactivate pathogens in red blood cell suspensions while maintaining red cell storage properties. Transfusion. 2006;46:213–219
  105. O'Brien SF, Yi QL, Fan W, et al. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion. 2007;47:316–325
  106. Kuhn TS. The structure of scientific revolutions. 2nd enlarged ed.. Chicago: The University of Chicago Press; 1970;

☆ This Consensus Conference took place at the Park Hyatt Hotel in Toronto, Ontario, Canada, on March 29 to 30, 2007, and was chaired by Dr Morris A. Blajchman.

PII: S0887-7963(07)00084-3

doi: 10.1016/j.tmrv.2007.09.001

Transfusion Medicine Reviews
Volume 22, Issue 1 , Pages 1-34 , January 2008

Article Tools

* Image Usage & Resolution